Advertisement

Topics

Selecta Biosciences, Inc. Company Profile

21:26 EDT 25th March 2017 | BioPortfolio

Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta’s fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selecta’s SVP™ platform technology is flexible to enable diverse vaccines and the company has created targeted antigen-specific Synthetic Vaccine Particles (tSVP™) and targeted antigen-specific tolerogenic Synthetic Vaccine Particles (t2SVP™).


News Articles [820 Associated News Articles listed on BioPortfolio]

BRIEF-JAMES FLYNN REPORTS 5.83 PCT PASSIVE STAKE IN SELECTA BIOSCIENCES

* JAMES FLYNN REPORTS 5.83 PERCENT PASSIVE STAKE IN SELECTA BIOSCIENCES INC AS OF JANUARY 12 - SEC FILING Source text - http://bit.ly/2jqsktO Further company coverage:

Spark signs licensing deal with Selecta for up to $460M-plus

Spark Therapeutics has entered into a licensing deal with Selecta Biosciences, gaining exclusive global rights to its Synthet -More- 

Selecta hires Lonza to make synthetic vector delivered gene therapy

Selecta Biosciences Inc. has hired Swiss contractor Lonza to make a gene therapy candidate for the metabolic disease, Methylmalonic Acidemia (MMA).

Spark Therapeutics Licenses Selecta's SVP Platform, Options to Four Genetic Targets

Spark Therapeutics has gained exclusive worldwide rights to Selecta Biosciences’ Synthetic Vaccine Particles (SVP™) platform and exclusive options for up to four additional undisclosed genetic tar...

Selecta Biosciences: Educating The Immune System

Selecta Biosciences to Participate in Two Investor Conferences in February

WATERTOWN, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific imm...

Selecta Biosciences to Present at Two Upcoming Investor Conferences in November

WATERTOWN, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immun...

BRIEF-Spark Therapeutics entered into license, option agreement with Selecta

* Spark Therapeutics Inc - on December 2, 2016 entered into a license and option agreement with Selecta Biosciences Inc Source text (http://bit.ly/2gfykZ8) Further company coverage:

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [102 Associated PubMed Articles listed on BioPortfolio]

Metabolic and reproductive plasticity of core and marginal populations of the eurythermic saline water bug Sigara selecta (Hemiptera: Corixidae) in a climate change context.

Ongoing climate change is driving dramatic range shifts in diverse taxa worldwide, and species responses to global change are likely to be determined largely by population responses at geographical ra...

Introduction.

cDNA Library Enrichment of Full Length Transcripts for SMRT Long Read Sequencing.

The utility of genome assemblies does not only rely on the quality of the assembled genome sequence, but also on the quality of the gene annotations. The Pacific Biosciences Iso-Seq technology is a po...

Back cover.

Front cover.

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients

Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosup...

Companies [331 Associated Companies listed on BioPortfolio]

Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen...

Selecta Biosciences, Inc. and Genethon

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical comp...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

More Information about "Selecta Biosciences, Inc." on BioPortfolio

We have published hundreds of Selecta Biosciences, Inc. news stories on BioPortfolio along with dozens of Selecta Biosciences, Inc. Clinical Trials and PubMed Articles about Selecta Biosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Selecta Biosciences, Inc. Companies in our database. You can also find out about relevant Selecta Biosciences, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record